Your session is about to expire
← Back to Search
Anti-CD38 A2 DAR T Cells for Multiple Myeloma
Study Summary
This trial is testing a new drug for subjects with multiple myeloma who have relapsed or who are refractory to current treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your oxygen level when breathing normally is at least 92%.I have active plasma cell leukemia.I have had cancer spread to my brain or spine.My multiple myeloma has returned or didn't respond after treatment.You are expected to live for at least 12 more weeks.My heart's pumping ability is below 40%.I haven't had any systemic therapy for my multiple myeloma in the last 14 days.I have a history of brain or heart disease that may increase my risk in this study.My blood clotting tests are abnormal, but I am on a stable dose of blood thinner.I have HIV/AIDS or chronic hepatitis B or C.I do not have any major health or mental issues preventing me from joining the study.I have another cancer besides multiple myeloma that is either not in remission or was treated in the last 3 years.I currently have an infection.I had a stem cell transplant less than 6 months ago, have GvHD, or am on immunosuppressants.I have a tumor outside of my bone marrow.I have not had any cell therapy in the last 8 weeks.I have no lasting side effects from cancer treatment worse than Grade 2.My cancer shows CD38 on the cell surface.I need help with my daily activities due to my health condition.You have abnormal levels of certain proteins in your blood or bone marrow.Your blood tests show low levels of hemoglobin, platelets, or neutrophils unless it's related to your condition.Your blood tests show high levels of creatinine, AST, or β2 microglobulin before starting the study.
- Group 1: STI-1492
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any openings for prospective participants in this research endeavor?
"According to clinicaltrials.gov, this study is still searching for recruits; it was first made public on December 30th 2022 before being altered on November 14th of the same year."
Could you elaborate on the safety profile of STI-1492?
"Due to the experimental nature of this Phase 1 trial, limited evidence exists to support both efficacy and safety. Thus it received a relatively low score of 1."
How many persons are participating in this clinical trial?
"Affirmative. According to records on clinicaltrials.gov, this experiment is presently searching for individuals interested in participating. The trial was first unveiled on December 30th 2022 and has since been updated as of November 14th 2022. 54 participants need to be enlisted from 3 disparate sites."
Share this study with friends
Copy Link
Messenger